A Phase I Study of TAS102 Plus Talazoparib in Advanced Colorectal (CRC) and Esophagogastric (EGC) Adenocarcinomas.
07:30am - 03:35pm EDT - April 5, 2024
07:30am - 03:35pm EDT - April 5, 2024
Abstract: JNCCN23-0513 https://jnccn.org/view/journal...
Author(s):
- Christos Fountzilas, MD, Roswell Park Comprehensive Cancer Center
Tags: Member Institution NCCN Foundation Young Investigator Award Clinical Oncology
| Display Label | Action |
|---|---|
| TAS102 PARPi NCCN 2024 poster.pdf | Download Handout |